drugset / Trial / NCT05090566
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
Timeline
- Start
- 2021-10-27
- Primary completion
- 2025-02-13
- Completion
- 2026-03-11
Outcome
Outcome not reported
Stopped (Business): “A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Elranatamab | Monoclonal antibody | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |
| Subject | Nirogacestat | Small molecule | — | — |